Purdue Pharma Provides Aid to Victims of Earthquake Disaster in Haiti

Company Donates Close to $5 Million in Pharmaceutical Products; Provides Cash Donation

Stamford, Conn. – January 20, 2010 – Purdue Pharma L.P. and its associated U.S. companies are donating close to $5 million in pharmaceutical products to aid the victims of the earthquake disaster in Haiti. The Company is also making a cash donation of $25,000 to AmeriCares and is matching employee cash donations dollar for dollar to AmeriCares and the American Red Cross to further support to those organizations’ relief efforts.

“The devastation caused by this earthquake is horrific and our hearts and prayers go out to the victims and their families,” said John H. Stewart, President and CEO of Purdue Pharma L.P. “I’m particularly proud of our employees who have demonstrated such tremendous generosity and concern for the people of Haiti.”

Purdue is donating close to $5 million of Ryzolt® (tramadol HCl extended-release tablets) and Betadine® (povidone-iodine) Solution and Betadine® Surgical Scrub antiseptics to AmeriCares. The company is exploring whether additional shipments of Ryzolt and Betadine can be distributed in Haiti through other relief agencies.

Purdue Pharma L.P. and its associated U.S. companies are privately held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

# # #

Contact:

Shirley Johnson
(203) 588-7681
shirley.johnson@pharma.com

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.